What we are studying
The current standard management for patients with leiomyosarcoma of the uterus which has been completely removed by surgery is to follow patients closely to check if the leiomyosarcoma comes back. Many patients may remain without any evidence of the cancer coming back after having had surgery to take out the leiomyosarcoma. In some patients, however, the leiomyosarcoma does come back.
Currently when leiomyosarcoma comes back (recurs) the leiomyosarcoma may be treated with chemotherapy. There are several chemotherapy drugs that can shrink leiomyosarcoma tumors. These include the combination treatment of gemcitabine and docetaxel, and another drug called doxorubicin. In this study, we are looking to see if giving chemotherapy with gemcitabine plus docetaxel, followed by doxorubicin, to patients whose leiomyosarcoma was found only in the uterus, decreases the chance that the leiomyosarcoma will come back (recur). In this study half of the patients will be treated with chemotherapy and also followed to see if the disease comes back.